1044 NORTH U.S. HIGHWAY ONE, JUPITER, FL
Secures $2.9 Million Through Registered Direct Offering and Concurrent Private Placement
Announces Second Quarter 2026 Financial Results
Announces Continued Listing on The Nasdaq Capital Market
2026 Annual Meeting Results; Election of Seth J. Herbst, M.D. as Director
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Highlights Accelerated Interest in C1 Biomanufacturing Platform Amid Ebola Preparedness Activities and Growing Commercial Adoption
And Scripps Research Collaborate on Rapid-Response Hantavirus Antibody and Vaccine Development
Announces First Quarter 2026 Financial Results and Highlights Recent Company Progress
Q2
Q1
Amended Annual Report
FY 2025
Q3
FY 2024
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Definitive Proxy Statement
PRE 14A
Additional Proxy Materials
Amended Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Schedule 13G - Ownership Report
Correspondence
Submission Upload